Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. Under normal conditions, these oncogenes regulate the flow of cellular growth signaling. However, mutations or molecular alterations can result in overactivity, setting off a signal cascade that drives uncontrolled proliferation. Entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK, disrupting signaling and thereby leading to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. In vivo models of entrectinib in TrkB expressing neuroblastoma cells suggest that the drug may enhance the efficacy of conventional chemotherapy.
4 Drug Overview
5 Product Profiles
5 entrectinib : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
6 Figure 24: Datamonitor Healthcare’s drug assessment summary for Cyramza in non-small cell lung cancer
7 Figure 84: Datamonitor Healthcare’s drug assessment summary for entrectinib in non-small cell lung cancer
8 Figure 94: Entrectinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
7 Table 1: Entrectinib pivotal trial data in non-small cell lung cancer
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.